Samsung Biologics Sets Q1 Sales Record...Eyes KRW 5T Year
[Seungkwon Kim, Edaily Reporter] Samsung Biologics reported record-breaking earnings for the first quarter of 2025, driven by increased operations at its fourth plant and favorable foreign exchange rates.
The South Korean contract drug manufacturer posted consolidated revenue of KRW 1.2983 trillion and an operating profit of KRW 486.7 billion for the quarter.
Revenue surged 37.1% year over year, while operating profit more than doubled, rising 119.9%.
뉴스픽의 주요 문장 추출 기술을 사용하여 “이데일리” 기사 내용을 3줄로 요약한 결과입니다. 일부 누락된 내용이 있어 전반적인 이해를 위해서는 본문 전체 읽기를 권장합니다.
